Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

AVeta · Hormone-free solution for vaginal atrophy

HORIZONStatus: CLOSED1 April 202231 December 2024EU funding €2,500,000Call HORIZON-EIC-2021-ACCELERATOROPEN-01

Vaginal Atrophy (VA) is a chronic and progressive condition. VA impacts on the quality of life, relationships, everyday activities and confidence of women sufferers. It is associated with thinning, drying and inflammation of the vaginal tissue. It is experienced by 80% of all women globally and is the most common symptom of the menopause. Over 70% of Breast Cancer Survivors will also suffer from VA due to side effects of chemotherapy and the cancer-blocker drugs they take further exacerbate symptoms of VA. Current treatment options for VA, primarily pharmaceuticals are either ineffective or poorly tolerated. In the EU and US, 3.6m patients of VA reject existing treatments. AVeta- a medical device delivering the only hormone free, affordable and safe targeted therapy for all women suffering from VA. Solution is based on pathophysiology of wound healing and will be prescribed by a Clinician in an outpatient setting and women will self-administer the therapy monthly at home.

Consortium · 1 organisation

coordinator

AVETA MEDICAL LIMITED

IE · €2,500,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.